Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infectious Diseases

Set Alert for Infectious Diseases

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Research & Development Clinical Trials

GSK Tries To Chase Down Pfizer With Phase III Pentavalent Meningococcal Vaccine Data

Phase III data for a vaccine combining Bexsero and Menveo demonstrated non-inferiority. GSK hopes to file it for approval soon, while Pfizer’s candidate has an October FDA action date.

Clinical Trials Vaccines

ViiV’s Bid To Switch HIV Patients To Cabenuva Boosted By Biktarvy Head-To-Head

A new head-to-head proves Cabenuva is a match for Gilead’s Biktarvy, which should boost uptake of the long-acting HIV treatment.

Companies Clinical Trials

Merck & Co. And Gates Foundation Drug Hunters Hopeful Of A TB Breakthrough

The Bill & Melinda Gates Foundation has brought together big pharma companies and academic institutes in a non-profit venture to find new drugs to improve tuberculosis treatment. One participant, Merck & Co, talks to Scrip about two promising novel molecules that it discovered for the Foundation’s Medical Research Institute to develop.

Clinical Trials Infectious Diseases

GSK Ends Pact with Vir For New COVID Treatments

Its Xevudy partner GSK is pulling out but Vir is going to carry on looking for new COVID-19 solutions independently, or with other partners.

Coronavirus COVID-19 Deals

Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark

Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.

Sales & Earnings Cancer

GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle

Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.

Infectious Diseases Business Strategies

Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology

Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.

Strategy Oncology

Aridis' Monoclonal Antibody Rouses Analyst Optimism Despite Pneumonia Phase III Miss

The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.

Clinical Trials Infectious Diseases

10 Clinical Trials To Watch Out For In 2023

Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.

Scrip Perspectives Clinical Trials

Vir CEO George Scangos, Set To Retire, Reflects On A Long Career In Biotech

Bayer pharmaceuticals executive Marianne De Backer will succeed Scangos at Vir, tasked with advancing several mid-stage programs in areas like hepatitis B and influenza to late-stage development.

Leadership Business Strategies

Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market

Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.

Infectious Diseases Respiratory
See All
UsernamePublicRestriction

Register